Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 22:24:06 GMT 2025
by
admin
on
Tue Apr 01 22:24:06 GMT 2025
|
| Protein Type | MONOCLONAL ANTIBODY |
| Protein Sub Type | IGG1 |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
DW4CE8MKS9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C163020
Created by
admin on Tue Apr 01 22:24:06 GMT 2025 , Edited by admin on Tue Apr 01 22:24:06 GMT 2025
|
PRIMARY | |||
|
11081
Created by
admin on Tue Apr 01 22:24:06 GMT 2025 , Edited by admin on Tue Apr 01 22:24:06 GMT 2025
|
PRIMARY | |||
|
2226393-85-5
Created by
admin on Tue Apr 01 22:24:06 GMT 2025 , Edited by admin on Tue Apr 01 22:24:06 GMT 2025
|
PRIMARY | |||
|
DW4CE8MKS9
Created by
admin on Tue Apr 01 22:24:06 GMT 2025 , Edited by admin on Tue Apr 01 22:24:06 GMT 2025
|
PRIMARY | |||
|
300000010817
Created by
admin on Tue Apr 01 22:24:06 GMT 2025 , Edited by admin on Tue Apr 01 22:24:06 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_22 | 1_95 |
| 1_151 | 1_207 |
| 1_268 | 1_328 |
| 1_374 | 1_432 |
| 2_22 | 2_95 |
| 2_151 | 2_207 |
| 2_268 | 2_328 |
| 2_374 | 2_432 |
| 1_227 | 3_214 |
| 1_233 | 2_233 |
| 1_236 | 2_236 |
| 2_227 | 4_214 |
| 3_23 | 3_89 |
| 3_134 | 3_194 |
| 4_23 | 4_89 |
| 4_134 | 4_194 |
| Glycosylation Type | MAMMALIAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_304 |
| N | 2_304 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IPH5401 is a therapeutic human antibody that specifically binds and blocks C5a receptors (C5aR) expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils. IPH5401 blocks the binding of C5a to C5aR, thereby reducing the accumulation and activation of MDSC and neutrophils in tumors. Treatment with IPH5401 may unleash anti-tumor activities of T cells and NK cells.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|